LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY E Crusoe; T Facon; P Moreau; I Spicka; K Suzuki; K Yong; J Mikhael; T Fukao; N Armstrong; T Martin;

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS A Maiolino; R Hajek; T Jelinek; P Moreau; T Martin; L Pour; G Mikala; A Symeonidis; S Bringhen; A Rawlings; ML Risse; H Vande-Velde; I Spicka;

DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS NJ Bahlis; SZ Usmani; T Facon; S Zweegman; C Venner; M Braunstein; L Pour; J Marti; A Maiolino; V Hungria;